State Directory

Provider Records in Minnesota

GLP1Search tracks 213 provider records across 72 Minnesota cities. 0 records include explicit GLP-1, medication, or peptide treatment evidence; 213 are directory-only healthcare/provider records that need direct confirmation.

Provider Records

213

Cities

72

Treatment Evidence

0

Directory-Only

213

Market Snapshot

Where source-ready GLP-1 records are concentrated in Minnesota

The Minnesota source-ready local index is led by its largest indexed cities. Across the state, 97% of provider records include phone plus address or website coverage, 0% list public pricing, and 50% carry an upstream source/place signal.

Data Complete

97%

Pricing Visible

0%

Source Flagged

50%

Top Minnesota cities for source-ready GLP-1 records

All covered cities in Minnesota

Afton1
Albany1
Alexandria4
Andover1
Apple Valley5
Austin1
Baxter4
Bemidji1
Blaine3
Bloomington5
Brainerd2
Breckenridge1
Burnsville1
Chanhassen3
Chaska3
Coon Rapids1
Cottage Grove1
Crosby1
Detroit Lakes1
Duluth2
Eagan1
East Grand Forks1
Edina24
Elk River1
Excelsior2
Fairmont1
Glenwood1
Golden Valley1
Grand Rapids2
Hastings1
Hermantown1
Hibbing1
Hopkins1
Hutchinson2
Lakeville4
Little Falls1
Maple Grove8
Maplewood2
Marshall1
Medina1
Menahga1
Minneapolis39
Minnetonka9
Moorhead1
New London1
Nisswa1
North Mankato1
Northfield1
Oakdale2
Orono1
Osseo1
Pequot Lakes1
Perham4
Plymouth5
Princeton1
Prior Lake2
Robbinsdale2
Rochester3
Roseville4
Savage1
Shoreview1
St Cloud3
St Joseph1
St Louis Park3
St Paul7
Stillwater1
Wadena1
Wayzata6
White Bear Lake1
Willmar1
Woodbury7
Wyoming1

Questions about provider records in Minnesota

How many providers are listed?

GLP1Search lists 213 provider records across 72 cities in Minnesota, including 0 treatment-evidence records and 213 directory-only records to verify.

Which cities have the most listings?

Minneapolis (39), Edina (24), Minnetonka (9), Maple Grove (8), St Paul (7) currently have the highest listing density in Minnesota.

What should patients compare?

Compare licensed clinical oversight, medication source, pharmacy type, public pricing, follow-up cadence, side-effect support, and whether the clinic documents semaglutide or tirzepatide availability.